New RNA vaccine trial targets deadly brain tumors
NCT ID NCT06389591
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether RNA-lipid particle vaccines can be safely made and given to adults with recurrent glioblastoma, an aggressive brain cancer. The vaccines are designed to teach the immune system to attack tumor cells. The study will enroll 24 participants and focus on safety and manufacturing feasibility.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RNA-lipid particle (RNA-LP) vaccines (pp65 RNA and personalized tumor mRNA)
What this could lead to
If this trial succeeds, it could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong
This is a very early phase 1 trial with only 24 participants, so it is too small to prove effectiveness. The vaccines may not trigger a strong enough immune response or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UF Health
RECRUITINGGainesville, Florida, 32608, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••